Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 4, 2008, Pages 605-620

  Zerbe, Laura K ^a   Dwyer Nield, Lori D ^a   Fritz, Jason M ^a   Redente, Elizabeth F ^a   Shroyer, Robert J ^a   Conklin, Elizabeth ^b   Kane, Shawn ^b   Tucker, Chris ^b   Eckhardt, S Gail ^a   Gustafson, Daniel L ^c   Iwata, Kenneth K ^b   Malkinson, Alvin M ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b OSI PHARMACEUTICALS INC   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Early stage lung cancer; Erlotinib; Primary mouse lung tumor model

Indexed keywords

BETA CYCLODEXTRIN SULFOBUTYL ETHER; CARCINOGEN; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; OSI 420; PROTEIN TYROSINE KINASE; URETHAN;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CODON; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG TUMOR LEVEL; EARLY CANCER; EGFR GENE; FEMALE; GENDER; GENE MUTATION; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR GENE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR MODEL;

ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INJECTIONS, INTRAPERITONEAL; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED STRAINS; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEX FACTORS;

EID: 47549089901     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0644-z     Document Type: Article

References (61)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global statistics, 2002 CA Cancer J Clin 55 2 74 108
2. American Cancer Society (2007) Cancer facts and figures 2007. American Cancer Society, Atlanta
3. FR Hirsch M Varella-Garcia PA Bunn MV Di Maria R Veve RM Bremnes AE Baron C Zeng WA Franklin 2003 Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis J Clin Oncol 21 3798 3807
4. CL Arteaga 2002 Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7 Suppl 4 31 39
5. J Brabender KD Danenberg R Metzger PM Schneider J Park D Salonga AH Holscher PV Danenberg 2001 Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival Clin Cancer Res 7 1850 1855
6. Y Yarden MX Sliwkowski 2001 Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 127 137
7. RN Jorissen F Walker N Pouliot TP Garrett CW Ward AW Burgess 2003 Epidermal growth factor receptor: mechanisms of activation and signalling Exp Cell Res 284 31 53
8. W Pao VA Miller 2005 Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions J Clin Oncol 23 2556 2568
9. NE Hynes HA Lane 2005 ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 341 354
10. M Ono M Kuwano 2006 Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs Clin Cancer Res 12 7242 7251
11. RS Herbst PA Bunn Jr 2006 Targeting the epidermal growth factor receptor in non-small cell lung cancer Clin Cancer Res 9 5813 5824
12. F Ciardiello F De Vita M Orditura G Tortora 2004 The role of EGFR inhibitors in non small cell lung cancer Curr Opinion Oncol 16 130 135
13. FA Shepherd JR Pereira T Ciuleanu EH Tan V Hirsh S Thongprasert D Campos S Maoleekoonpiroj M Smylie R Martins M van Kooten M Dediu B Findlay DS Tu D Johnston A Bezjak G Clark P Santabarbara L Seymour 2005 Erlotinib in previously treated non-small-cell lung cancer New Engl J Med 353 123 132
14. MG Kris RB Natale RS Herbst TJ Lynch D Prager CP Belani JH Schiller K Kelly H Spiridonidis A Sandler KS Albain D Cella MK Wolf SD Averbuch JJ Ochs AC Kay 2003 Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer-a randomized trial JAMA 290 2149 2158
15. TJ Lynch DW Bell R Sordella S Gurubhagavatula RA Okimoto BW Brannigan PL Harris SM Haserlat JG Supko FG Haluska DN Louis DC Christiani J Settleman DA Haber 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib New Engl J Med 350 2129 2139
16. JG Paez PA Janne JC Lee S Tracy H Greulich S Gabriel P Herman FJ Kaye N Lindeman TJ Boggon K Naoki H Sasaki Y Fujii MJ Eck WR Sellers BE Johnson M Meyerson 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500
17. SV Sharma DW Bell J Settleman DA Haber 2007 Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 169 181
18. W Pao TY Wang GJ Riely VA Miller QL Pan M Ladanyi MF Zakowski RT Heelan MG Kris HE Varmus 2005 KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLOS Med 2 57 61
19. DA Eberhard BE Johnson LC Amler AD Goddard SL Heldens RS Herbst WL Ince PA Janne T Januario DH Johnson P Klein VA Miller MA Ostland DA Ramies D Sebisanovic JA Stinson YR Zhang S Seshagiri KJ Hillan 2005 Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol. 23 5900 5909
20. F Cappuzzo FR Hirsch E Rossi S Bartolini GL Ceresoli L Bemis J Haney S Witta K Danenberg I Domenichini V Ludovini E Magrini V Gregorc C Doglioni A Sidoni M Tonato WA Franklin L Crino PA Bunn Jr M Varella-Garcia 2005 Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 97 643 655
21. MS Tsao A Sakurada JC Cutz CQ Zhu S Kamel-Reid J Squire I Lorimer T Zhang N Liu M Daneshmand P Marrano SG da Cunha A Lagarde F Richardson L Seymour M Whitehead K Ding J Pater FA Shepherd 2005 Erlotinib in lung cancer-molecular and clinical predictors of outcome N Engl J Med 353 133 144
22. W Pao V Miller M Zakowski J Doherty K Politi I Sarkaria B Singh R Heelan V Rusch L Fulton E Mardis D Kupfer R Wilson M Kris H Varmus 2004 EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib PNAS 101 13306 13311
23. DW Bell TJ Lynch SM Haserlat PL Harris RA Okimoto BW Brannigan DC Sgroi B Muir MJ Riemenschneider RB Iacona AD Krebs DH Johnson G Giaccone RS Herbst C Manegold M Fukuoka MG Kris J Baselga JS Ochs DA Haber 2005 Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials J Clin Oncol 23 8081 8092
24. S Rodenhuis RJ Slebos 1992 Clinical significance of ras oncogene activation in human lung cancer Cancer Res 52 2665s 2669s
25. T Mitsudomi SM Steinberg HK Oie JL Mulshine R Phelps J Viallet H Pass JD Minna AF Gazdar 1991 Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent Cancer Res 51 4999 5002
26. MJ Moore D Goldstein J Hamm A Figer JR Hecht S Gallinger HJ Au P Murawa D Walde RA Wolff D Campos R Lim K Ding G Clark T Voskoglou-Nomikos M Ptasynski W Parulekar 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clin Trials Group J Clin Oncol 25 1960 1966
27. WA Franklin R Veve FR Hirsch BA Helfrich PA Bunn Jr 2002 Epidermal growth factor receptor family in lung cancer and premalignancy Sem Oncol 29 3 14
28. DT Merrick J Kittelson R Winterhalder G Kotantoulas S Ingeberg RL Keith TC Kennedy YE Miller WA Franklin FR Hirsch 2006 Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer Clin Cancer Res 12 2281 2288
29. AM Malkinson 1992 Primary lung tumors in mice: an experimentally manipulable model of human adenocarcinoma Cancer Res 52 2670s 2676s
30. AM Malkinson 1998 Molecular comparison of human and mouse pulmonary adenocarcinomas Exp Lung Res 24 541 555
31. AM Malkinson 2001 Primary lung tumors in mice as an aid for understanding, preventing, and treating human adenocarcinoma of the lung Lung Cancer 32 265 279
32. EP O'Donnell LK Zerbe LD Dwyer-Nield LR Kisley AM Malkinson 2006 Quantitative analysis of early chemically-induced pulmonary lesions in mice of varying susceptibilities to lung tumorigenesis Cancer Lett 241 197 202
33. RS Stearman L Dwyer-Nield L Zerbe SA Blaine Z Chan PA Bunn Jr GL Johnson FR Hirsch DT Merrick WA Franklin AE Baron RL Keith RA Nemenoff AM Malkinson MW Geraci 2005 Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model Am J Pathol 167 1763 1775
34. A Sweet-Cordero GC Tseng H You M Douglass B Huey D Albertson T Jacks 2006 Comparison of gene expression and DNA copy number changes in a murine model of lung cancer Genes Chromosomes Cancer 45 338 348
35. GH Fisher SL Wellen D Klimstra JM Lenczowski JW Tichelaar MJ Lizak JA Whitsett A Koretsky HE Varmus 2001 Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes Genes Dev 15 3249 3262
36. L Johnson K Mercer D Greenbaum RT Bronson D Crowley DA Tuveson T Jacks 2001 Somatic activation of the K-ras oncogene causes early onset lung cancer in mice Nature 410 1111 1116
37. M Hamilton JL Wolf J Rusk SE Beard GM Clark K Witt PJ Cagnoni 2006 Effects of smoking on the pharmacokinetics of erlotinib Clin Cancer Res 12 2166 2171
38. AM Malkinson DS Beer 1983 Major effect on susceptibility to urethan-induced pulmonary adenoma by a single gene in BALB/cBy mice J Natl Cancer Inst 70 931 936
39. McRae G, Lazaro L, Liao L, Papadopoulos P, Osdon M (2002) Validation of a high performance liquid chromatographic method for the determination of OSI-774 and OSI-420 in human plasma (heparin) specific to OSI Pharmaceuticals. MDS Pharma Services, Montreal
40. Conklin E, Hamilton M, Drolet D, Keatly K, Tucker C (2004) Method protocol and corresponding validation report for the quantification of OSI-774 and major metabolite OSI-420/413 in human EDTA plasma by HPLC/MS/MS. OSI Pharmaceuticals IBC, assignee
41. OH Lowry NJ Rosebrough AL Farr RJ Randall 1951 Protein measurement with the folin phenol reagent J Biol Chem 193 265 275
42. J Ling KA Johnson Z Miao A Rakhit MP Pantze M Hamilton BL Lum C Prakash 2006 Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers Drug Metab Dispos 34 420 426
43. S Thomson E Buck F Petti G Griffin E Brown N Ramnarine KK Iwata N Gibson JD Haley 2005 Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition Cancer Res 65 9455 9462
44. RL Yauch T Januario DA Eberhard G Cavet W Zhu L Fu TQ Pham R Soriano J Stinson S Seshagiri Z Modrusan C Lin V O-Neill LC Amler 2005 Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients Clin Cancer Res 11 8686 8698
45. M You U Candrian RR Maronpot GD Stoner MW Anderson 1989 Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse PNAS 86 3070 3074
46. EO Nuzum AM Malkinson DG Beer 1990 Specific ki-ras codon-61 mutations may determine the development of urethane-induced mouse lung adenomas or adenocarcinomas Molec Carcinog 3 287 295
47. M Malumbres M Barbacid 2003 RAS oncogenes: the first 30 years Nat Rev Cancer 3 459 465
48. RN Jorissen F Walker N Pouliot TPJ Garrett CW Ward AW Burgess 2003 Epidermal growth factor receptor:mechanisms of activation and signalling Exp Cell Res 284 31 53
49. LS Van Winkle AD Gunderson JA Shimizu GL Baker CD Brown 2002 Gender differences in naphthalene metabolism and naphthalene-induced acute lung injury Am J Physiol Lung Cell Molec Physiol 282 L1122 L1134
50. M Hamilton JL Wolf D Zborowski J Lu BL Lum K Ding GM Clark A Rakhit L Seymour AM Ptaszynski J Rusk F Shepherd 2005 Tarceva (erlotinib) exposure/effects (EE) analysis from a phase III study in advanced NSCLC. Effect of smoking on the PK of erlotinib Proc Am Assoc Cancer Res 46 1451
51. Tarceva [prescribing information] (2005) Genentech, Melville, NY. Am Cancer Society 52:23-47
52. P Frohna J Lu S Eppler M Hamilton J Wolf A Rakhit J Ling SR Kenkare-Mitra BL Lum 2006 Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects J Clin Pharmacol 46 282 290
53. B Higgins K Kolinsky M Smith G Beck M Rashed V Adames M Linn E Wheeldon L Gand H Birnboeck G Hoffmann 2004 Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models Anti-Cancer Drugs 15 503 512
54. PG Forkert A Parkinson LG Thaete AM Malkinson 1992 Resistance of murine lung-tumors to xenobiotic-induced cytotoxicity Cancer Res 52 6797 6803
55. KM Gressani S Leone-Kabler MG O'Sullivan LD Case AM Malkinson MS Miller 1999 Strain-dependent lung tumor formation in mice transplacentally exposed to 3-methylcholanthrene and post-natally exposed to butylated hydroxytoluene Carcinogenesis 20 2159 2165
56. N Fujimoto M Wislez J Zhang K Iwanaga J Dackor AE Hanna S Kalyankrishna DD Cody RE Price M Sato JW Shay JD Minna M Peyton X Tang E Massarelli R Herbst DW Threadgill II Wistuba JM Kurie 2005 High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor Cancer Res 65 11478 11485
57. K Politi MF Zakowski PD Fan EA Schonfeld W Pao HE Varmus 2006 Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors Genes Develop 20 1496 1510
58. Y Yan Y Lu M Wang H Vikis R Yao Y Wang RA Lubet M You 2006 Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer Mol Cancer Res 4 971 981
59. T Barka 1980 Biologically active polypeptides in submandibular glands J Histochem Cytochem 28 836 859
60. A Potti AK Ganti 2006 Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future Expert Opin Biol Ther 6 709 716
61. RW Ashton JR Jett 2005 Screening for non-small cell lung cancer Semin Oncol 32 253 258